Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Debt (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Total Debt for 11 consecutive years, with $203.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 50.39% year-over-year to $203.1 million, compared with a TTM value of $203.1 million through Dec 2025, down 50.39%, and an annual FY2025 reading of $254.9 million, down 35.17% over the prior year.
  • Total Debt was $203.1 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $254.9 million in the prior quarter.
  • Across five years, Total Debt topped out at $409.4 million in Q4 2024 and bottomed at $203.1 million in Q4 2025.